Shanghai Shyndec Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Shanghai Shyndec Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013519
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Shanghai Shyndec Pharmaceutical Co Ltd (Shanghai Shyndec) a subsidiary of China National Pharmaceutical Group Corp, is a pharmaceutical company which focuses on the production and sale of active pharmaceutical ingredients (API’s), oral preparations and finished drugs. Its product portfolio includes macrolide antibiotics, anti-virals, anti-tumor, cardiovascular, hormones, cough medicines, prostate disease medication, sedative hyponotics, diabetes medication among others. The company also provides topical preparations such as gynecological suppositories, dermatology drugs and others. Shanghai Shyndec offers drugs for treatment of cardiovascular disease which include enalapril maleate tablets, nifedipine controlled release tablets and others. It has three production facilities which manufacture and distribute the pharmaceutical products internationally. Shanghai Shyndec is headquartered in Shanghai, China.

Shanghai Shyndec Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 10
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 11
Acquisition 12
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 12
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 13
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 14
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 15
Shanghai Shyndec Pharmaceutical Co Ltd – Key Competitors 16
Shanghai Shyndec Pharmaceutical Co Ltd – Key Employees 17
Shanghai Shyndec Pharmaceutical Co Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Shanghai Shyndec Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Shanghai Shyndec Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Shanghai Shyndec Pharma to Raise USD291 Million in Private Placement of Shares 10
Shanghai Shyndec Pharma Recives Government Approval to Raise USD245 Million in Private Placement of Shares 11
Shanghai Shyndec Pharma to Acquire Stakes in 12 Pharma Companies for USD1.2 Billion 12
Shanghai Shyndec Pharma To Acquire Remaining 30% Stake In Sinopharm Rongsheng Pharma For US$49 Million 13
Shanghai Shyndec Pharma Completes Acquisition Of 86.86% Stake In Wuhan Zhongliang Pharma From China State Institute Of Pharma For US$16 Million 14
Shanghai Shyndec Pharma Acquires 72% Stake In Sinopharm Chuan Kang Pharma For US$2.8 Million 15
Shanghai Shyndec Pharmaceutical Co Ltd, Key Competitors 16
Shanghai Shyndec Pharmaceutical Co Ltd, Key Employees 17
Shanghai Shyndec Pharmaceutical Co Ltd, Other Locations 18
Shanghai Shyndec Pharmaceutical Co Ltd, Subsidiaries 18

★海外企業調査レポート[Shanghai Shyndec Pharmaceutical Co Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ONGC Videsh Ltd:企業のM&A・事業提携・投資動向
    ONGC Videsh Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ONGC Videsh Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Cosmo Pharmaceuticals NV (COPN):企業の財務・戦略的SWOT分析
    Summary Cosmo Pharmaceuticals NV (Cosmo) is a pharmaceutical company that develops drugs for the treatment of gastro-intestinal diseases. The company develops its pharmaceutical products based on its multi matrix technology. Its proprietary clinical development pipeline intended for the treatment of …
  • AIG Asia Pacific Insurance Pte. Ltd.:企業の戦略・SWOT・財務情報
    AIG Asia Pacific Insurance Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary AIG Asia Pacific Insurance Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Checkpoint Therapeutics Inc (CKPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Checkpoint Therapeutics Inc (Checkpoint Therapeutics), a subsidiary of Fortress Biotech Inc, is a clinical-stage biopharmaceutical company that acquires, develops and commercializes non-chemotherapy and immune enhanced combination treatments for the treatment of solid tumor cancers. The comp …
  • Lanxess AG (LXS):企業の財務・戦略的SWOT分析
    Lanxess AG (LXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • John Wood Group Plc (WG.):電力:M&Aディール及び事業提携情報
    Summary John Wood Group plc (Wood) is a provider of project, engineering and technical services. The company offers comprehensive solutions that improve the performance of customers' industrial assets across the asset life cycle. Its services span from concept to decommissioning and include asset so …
  • Cara Therapeutics Inc (CARA):医療機器:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • The Goldman Sachs Group Inc (GS):企業の財務・戦略的SWOT分析
    The Goldman Sachs Group Inc (GS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Allscripts Healthcare Solutions Inc (MDRX):製薬・医療:M&Aディール及び事業提携情報
    Summary Allscripts Healthcare Solutions Inc (Allscripts), formerly Allscripts-Misys Healthcare Solutions, Inc., is a provider of healthcare information technology solutions. The company’s major solutions include Electronic Health Records (EHR), Financial Management Solutions, Population Health Manag …
  • Tyson Foods Inc:企業のM&A・事業提携・投資動向
    Tyson Foods Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tyson Foods Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Precision Drilling Corp (PD):企業の財務・戦略的SWOT分析
    Precision Drilling Corp (PD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Hainan Airlines Co., Ltd.:企業のM&A・事業提携・投資動向
    Hainan Airlines Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hainan Airlines Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisi …
  • Eli Lilly and Company (India) Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Eli Lilly and Company (India) Pvt Ltd (Eli Lilly), a subsidiary of Eli Lilly and Company is a drug company that manufactures medicines. The company offers pharmaceutical products for the therapeutic areas such as diabetes, cancer, osteoporosis, cardiovascular disorders and growth-hormone def …
  • PetroChina Co Ltd (857)-エネルギー分野:企業M&A・提携分析
    Summary PetroChina Company Limited (PetroChina), a subsidiary of China National Petroleum Corporation, is an oil and gas company that explores for, develops and produces crude oil and natural gas; refines crude oil and petroleum products; and produces and sells basic and derivative chemical products …
  • General Mills Inc:企業の戦略・SWOT・財務情報
    General Mills Inc - Strategy, SWOT and Corporate Finance Report Summary General Mills Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • BioScrip Inc (BIOS):企業の財務・戦略的SWOT分析
    BioScrip Inc (BIOS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Putnam Investments LLC:企業の戦略的SWOT分析
    Putnam Investments LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Wellington Management Company LLP:企業のM&A・事業提携・投資動向
    Wellington Management Company LLP - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Wellington Management Company LLP Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Gjensidige Forsikring ASA :企業のM&A・事業提携・投資動向
    Gjensidige Forsikring ASA  - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Gjensidige Forsikring ASA  Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • RPC Group Plc (RPC):企業の財務・戦略的SWOT分析
    RPC Group Plc (RPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆